A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
Sverre Lehmann,1,2 Thomas Ringbæk,3 Anders Løkke,4 Ludger Grote,5 Jan Hedner,6 Eva Lindberg7 1Department of Thoracic Medicine, Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, Bergen, Norway; 2Section of Thoracic Medicine, Department of Clinical Sc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-01-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-randomized-trial-to-determine-the-impact-of-indacaterolglycopyrroniu-peer-reviewed-article-COPD |
| _version_ | 1818788795119566848 |
|---|---|
| author | Lehmann S Ringbæk T Løkke A Grote L Hedner J Lindberg E |
| author_facet | Lehmann S Ringbæk T Løkke A Grote L Hedner J Lindberg E |
| author_sort | Lehmann S |
| collection | DOAJ |
| description | Sverre Lehmann,1,2 Thomas Ringbæk,3 Anders Løkke,4 Ludger Grote,5 Jan Hedner,6 Eva Lindberg7 1Department of Thoracic Medicine, Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, Bergen, Norway; 2Section of Thoracic Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway; 3Department of Pulmonary Medicine, Hvidovre Hospital, University of Copenhagen, Denmark; 4Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark; 5Sleep Disorders Center, Department of Respiratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; 6Department of Internal Medicine, Center for Sleep and Wake Disorders, University of Gothenburg and Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; 7Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, SwedenPurpose: This study investigated the effect of dual bronchodilation with the long-acting β-receptor agonist/long-acting muscarinic antagonist combination, indacaterol/glycopyrronium (IND/GLY), on nighttime oxygenation, lung function, sleep quality, and symptoms in patients with moderate-to-severe COPD.Patients and methods: This was a 4-week, double-blind, multicenter, placebo-controlled, two-period crossover study. Patients were randomized in a 1:1 ratio to receive IND/GLY 110/50 µg once daily or matching placebo. The primary objective was to evaluate the effect of treatment with IND/GLY on mean nighttime oxygenation, compared with placebo. The secondary objective was to determine the time spent <90% in blood oxygen saturation (SpO2) compared with placebo. Exploratory objectives were to assess the effect of IND/GLY, compared with placebo, on sleep quality measured by the Medical Outcomes Study (MOS) Sleep Scale and the COPD and Asthma Sleep Impact Scale (CASIS) questionnaires and on symptoms assessed by COPD Assessment Test (CAT) questionnaire.Results: In total, 38 patients were randomized (n=22, IND/GLY; n=16, placebo). The change in nighttime oxygenation (SpO2) was similar, and there was a comparable difference in time spent <90% SpO2 between IND/GLY and placebo. Increases from baseline for the difference between IND/GLY and placebo for trough FEV1, FVC, and inspiratory capacity (P<0.05) were seen, with a corresponding reduction in residual volume and functional residual capacity (P<0.05). IND/GLY treatment showed an improvement in scores for CAT (P=0.0208), CASIS, and the MOS Sleep Scale measures, Sleep Problems Index I, Sleep Problems Index II (P=0.0315), Sleep Adequacy, Sleep Disturbance Scale, Somnolence Scale, and Short of Breath Scale (P=0.0031).Conclusion: In this study, IND/GLY 110/50 µg once daily improved symptoms, sleep quality, and lung function, but showed no effect on nighttime oxygenation in patients with moderate-to-severe COPD. Keywords: bronchodilator, sleep, hypoxia, quality of life, lung function |
| first_indexed | 2024-12-18T14:29:20Z |
| format | Article |
| id | doaj.art-17fd3f5887da418fb50d9fe0ec8e2ae1 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-18T14:29:20Z |
| publishDate | 2019-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-17fd3f5887da418fb50d9fe0ec8e2ae12022-12-21T21:04:37ZengDove Medical PressInternational Journal of COPD1178-20052019-01-01Volume 1419921043467A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep studyLehmann SRingbæk TLøkke AGrote LHedner JLindberg ESverre Lehmann,1,2 Thomas Ringbæk,3 Anders Løkke,4 Ludger Grote,5 Jan Hedner,6 Eva Lindberg7 1Department of Thoracic Medicine, Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, Bergen, Norway; 2Section of Thoracic Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway; 3Department of Pulmonary Medicine, Hvidovre Hospital, University of Copenhagen, Denmark; 4Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark; 5Sleep Disorders Center, Department of Respiratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; 6Department of Internal Medicine, Center for Sleep and Wake Disorders, University of Gothenburg and Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; 7Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, SwedenPurpose: This study investigated the effect of dual bronchodilation with the long-acting β-receptor agonist/long-acting muscarinic antagonist combination, indacaterol/glycopyrronium (IND/GLY), on nighttime oxygenation, lung function, sleep quality, and symptoms in patients with moderate-to-severe COPD.Patients and methods: This was a 4-week, double-blind, multicenter, placebo-controlled, two-period crossover study. Patients were randomized in a 1:1 ratio to receive IND/GLY 110/50 µg once daily or matching placebo. The primary objective was to evaluate the effect of treatment with IND/GLY on mean nighttime oxygenation, compared with placebo. The secondary objective was to determine the time spent <90% in blood oxygen saturation (SpO2) compared with placebo. Exploratory objectives were to assess the effect of IND/GLY, compared with placebo, on sleep quality measured by the Medical Outcomes Study (MOS) Sleep Scale and the COPD and Asthma Sleep Impact Scale (CASIS) questionnaires and on symptoms assessed by COPD Assessment Test (CAT) questionnaire.Results: In total, 38 patients were randomized (n=22, IND/GLY; n=16, placebo). The change in nighttime oxygenation (SpO2) was similar, and there was a comparable difference in time spent <90% SpO2 between IND/GLY and placebo. Increases from baseline for the difference between IND/GLY and placebo for trough FEV1, FVC, and inspiratory capacity (P<0.05) were seen, with a corresponding reduction in residual volume and functional residual capacity (P<0.05). IND/GLY treatment showed an improvement in scores for CAT (P=0.0208), CASIS, and the MOS Sleep Scale measures, Sleep Problems Index I, Sleep Problems Index II (P=0.0315), Sleep Adequacy, Sleep Disturbance Scale, Somnolence Scale, and Short of Breath Scale (P=0.0031).Conclusion: In this study, IND/GLY 110/50 µg once daily improved symptoms, sleep quality, and lung function, but showed no effect on nighttime oxygenation in patients with moderate-to-severe COPD. Keywords: bronchodilator, sleep, hypoxia, quality of life, lung functionhttps://www.dovepress.com/a-randomized-trial-to-determine-the-impact-of-indacaterolglycopyrroniu-peer-reviewed-article-COPDBronchodilatorsleephypoxiaquality of lifelung function |
| spellingShingle | Lehmann S Ringbæk T Løkke A Grote L Hedner J Lindberg E A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study International Journal of COPD Bronchodilator sleep hypoxia quality of life lung function |
| title | A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study |
| title_full | A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study |
| title_fullStr | A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study |
| title_full_unstemmed | A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study |
| title_short | A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study |
| title_sort | randomized trial to determine the impact of indacaterol glycopyrronium on nighttime oxygenation and symptoms in patients with moderate to severe copd the duosleep study |
| topic | Bronchodilator sleep hypoxia quality of life lung function |
| url | https://www.dovepress.com/a-randomized-trial-to-determine-the-impact-of-indacaterolglycopyrroniu-peer-reviewed-article-COPD |
| work_keys_str_mv | AT lehmanns arandomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT ringbækt arandomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT løkkea arandomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT grotel arandomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT hednerj arandomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT lindberge arandomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT lehmanns randomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT ringbækt randomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT løkkea randomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT grotel randomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT hednerj randomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy AT lindberge randomizedtrialtodeterminetheimpactofindacaterolglycopyrroniumonnighttimeoxygenationandsymptomsinpatientswithmoderatetoseverecopdtheduosleepstudy |